Sagimet Biosciences Inc. (SGMT) News
Follow Sagimet Biosciences Inc. (SGMT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet Biosciences Inc. (NASDAQ: SGMT ) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris. In January, the company shared topline data from the study. Concurrently, t
LIVE | Sep 30, 2026, 06:11 PM UTC
L
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial — SGMT Stock Surges Pre-Market
Shares of Sagimet Biosciences (SGMT) rose 13% in pre-market trading on Wednesday after the biotech firm reported promising long-term results for its experimental acne drug and raised fresh capital to fund its upcoming U.
CENTRAL_BANK | Sep 30, 2026, 12:17 PM UTC
L
Sagimet Biosciences Inc. (SGMT) Prices $115M Offering
Sagimet priced an underwritten offering of 8,750,010 Series A shares at $10.00 and pre-funded warrants for 2,750,010 shares at $9.9999, for expected gross proceeds of ~$115.0M. Closing is expected on or about Oct. 1, 202
EQUITY | Sep 30, 2026, 10:21 AM UTC
L
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathwa
EQUITY | Sep 30, 2026, 10:21 AM UTC
L
Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Sagimet Biosciences Inc. NASDAQ:SGMT
EQUITY | Sep 30, 2026, 10:15 AM UTC
L
Sagimet Announces Positive 52-Week Phase 3 OLE Results for Denifanstat, Preps U.S. Phase 3 Start
Sagimet announced positive 52-week open-label extension results for denifanstat showing sustained efficacy and tolerability.Key Highlights:Original SEC Filing: Sagimet Biosciences Inc. [ SGMT ] - 8-K - Sep. 30, 2026This
REGULATION | Sep 30, 2026, 10:13 AM UTC
L
Sagimet Biosciences Inc. (SGMT) Reports Positive 52-Week OLE Data for Denifanstat in Acne
Sagimet reported positive 52-week open-label extension results from Ascletis' Phase 3 trial of denifanstat in moderate to severe acne, with ~75—80% lesion reductions from original baseline among completers and generally
NEWS | Sep 30, 2026, 10:08 AM UTC
L
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathwa
NEWS | Sep 30, 2026, 10:08 AM UTC
L
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. NASDAQ:SGMT, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathwa
GEOPOLITICS | Sep 28, 2026, 11:08 AM UTC
L
Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:07 PM UTC
L
SGMT: Denifanstat's phase III acne trial launches soon, aiming for rapid market entry and long exclusivity
Denifanstat, a novel oral FASN inhibitor, is advancing to a US phase III acne trial with strong efficacy and safety data, targeting a large unmet need. Premium pricing and broad payer support are anticipated, with patent
EQUITY | Sep 09, 2026, 07:51 PM UTC
L
Barclays raises Sagimet Biosciences price target to $18
Barclays raised its Sagimet Biosciences price target to $18.00 a share from $8.00, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 01:20 PM UTC
L
Cantor Fitzgerald initiates Sagimet Biosciences with Overweight rating
Cantor Fitzgerald initiated Sagimet Biosciences with an Overweight rating and announced a $10.71/share price target.
EQUITY | Sep 09, 2026, 11:16 AM UTC
L
Sagimet Biosciences to participate in two upcoming investor conferences
Sagimet Biosciences said management will participate in two upcoming investor conferences, according to the company’s announcement.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
SGMT - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
SGMT - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:00 AM UTC
L
Sagimet Biosciences advances AURORA U.S. Phase 3 denifanstat trial
Sagimet Biosciences advances its AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.
EQUITY | Aug 25, 2026, 11:00 AM UTC
L
Sagimet Biosciences announces Nasdaq inducement grant under Rule 5635(c)(4)
Sagimet Biosciences (SGMT) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4), with the filing details not provided in the alert.
EQUITY | Aug 17, 2026, 08:28 PM UTC
H
Sagimet Biosciences gets FDA “Study May Proceed” letter for Phase 3
Sagimet Biosciences (SGMT) says the FDA issued a “Study May Proceed” letter and IND clearance for a Phase 3 trial in acne in adolescent and adult patients.
EQUITY | Aug 13, 2026, 11:01 AM UTC